ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Heart failure

February 5, 2019
In a letter to healthcare providers, the US FDA summarized a recent evaluation of a postapproval study of the Abiomed Impella RP system. In clinical trials, 73% of patients survived 30 days after device explant, hospital discharge, or to definitive intervention. In the postapproval study, just over 17% of patients met this goal.
January 30, 2019
Garbade and colleagues compared outcomes reported during the European Conformity (CE) Mark clinical trial of the HeartMate 3 left ventricular assist device (LVAD)  to outcomes for patients treated since the device came to market.
January 18, 2019
A good attempt to shed some light into the somewhat challenging concept of heart failure with preserved ejection fraction, on the occasion of a small randomized controlled trial on albuterol.
January 17, 2019
A succinct handy comment on a small series of left ventricular assist devices (LVAD) that is quite useful for a fast read on LVAD for surgeons and nonsurgeons.
December 26, 2018
A randomized controlled trial coauthored by the Editor-in-Chief of the host periodical on the risk management of multivessel diabetic coronopathy.
December 6, 2018
Gilles Dreyfus and colleagues share a decade of mitral reconstruction for degenerative posterior leaflet pathology in Harefield and Monaco (38 per year was the formidable average). The supplementary video is of particular educational value for the mitral surgeon and the cardiologist/TOE (TEE) specialist.
November 9, 2018
Interesting small randomized controlled trial that will definitely be widely discussed.
October 23, 2018
A post-market study (ELEVATE registry) of the fully magnetically levitated continuous flow HeartMate III left ventricular assist device (LVAD) found no pump thrombosis in 463 patients in Europe and Kazakhstan.
October 23, 2018
This video demonstrates a valve replacement surgery for a 55-year-old woman who presented with carcinoid heart disease caused by a primary ovarian carcinoid tumor.
October 12, 2018
The authors of this paper investigated the efficacy and safety of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) in 15 patients with hypertophic cardiomyopathy (HOCM). At six months, they found significant reductions in peak left ventricular outflow tract gradients and intraventricular septal thickness.

Pages